Crossmark

Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Crossref DOI link: https://doi.org/10.1016/j.rceng.2015.09.004

Published Print: 2015-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gómez Huelgas, R.

Gómez Peralta, F.

Carrillo Fernández, L.

Galve, E.

Casanueva, F.F.

Puig Domingo, M.

Mediavilla Bravo, J.J.

Orozco Beltrán, D.

Ena Muñoz, J.

Menéndez Torre, E.

Artola Menendez, S.

Mazón Ramos, P.

Monereo Megías, S.

Caixas Pedrágos, A.

López Simarro, F.

Álvarez Guisasola, F.
Funding

Funding for this research was provided by:

AstraZeneca Spain
License Information

Text and Data Mining valid from 2015-12-01
More Information

This article is maintained by: Elsevier

Article Title: Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Journal Title: Revista Clínica Española (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rceng.2015.09.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rce.2015.07.003

Content Type: article

Copyright: Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Medicina Interna (SEMI). All rights reserved.